Current information on the medical treatment of colorectal cancer was reviewed after a search of the literature through Medline. Publications from 1984 to present were surveyed. Appropriate adjuvant therapy increases overall survival and disease-free intervals. The treatment modalities of unresectable or metastatic tumors are disappointing, with at best 40% of patients experiencing short-lasting responses. Whenever possible, patients with advanced colorectal cancer should be enrolled in clinical trials.
Advanced Colorectal Cancer Meta-Analysis Project:Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J. Clin. Oncol., 10: 896–903, 1992.
2.
AllisonD.J., JordanH., O'HennessyO.: Therapeutic embo-lisation of the hepatic artery: a review of 75 procedures. Lancet, 8429: 595–598, 1985.
3.
AmeryW.K.: Immunopotentiation with levamisole in resectable bronchogenic cancer. A double blind placebo controlled trial. Br. Med. J., 3: 461–464, 1975.
4.
ArbuckS.G.: Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer, 63: 1036–1044, 1989.
5.
ArdalanB., SinghG., SilbermanH.,: A randomized phase I and II study of short-term infusion of high-dose fluorouracil with and without N-(phosphonacetyl)-1-aspartate acid in patients with advanced pancreatic and colorectal cancers. J. Clin. Oncol., 6: 1053–1058, 1988.
6.
ArnaudJ.P., BuyseM., NordlingerB., MartinF., PectorJ.C., ZittounP., AdloffA., DuezN.: Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial. Br. J. Surg., 76: 284–289, 1989.
7.
AsbunH.J., HughesK.S.: Management of recurrent and metastatic-colorectal carcinoma. Surg. Clin. N. Am., 73: 145–165, 1993.
8.
AstlerV.A., CollerF.A.: The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann. Surg., 139: 846, 1954.
9.
AugustD.A., OttowR.T., SugarbakerP.H.: Clinical perspectives on human colorectal cancer metastases. Cancer Metast. Rev., 3: 303–324, 1984.
10.
BancewiczJ., MacPhersonS.G., McVieJ.G.: Adjuvant chemotherapy and immunotherapy for colorectal cancer: preliminary communications. J. R. Soc. Med., 73: 197–199), 1980.
11.
BeahrsO.H.Staging of cancer of the colon and rectum. Cancer, 70(S): 1393–1396, 1992.
12.
BeartR.W., MoertelC.G., WieandH.S., LeighJ.E., Wind-schitlH.E., van HeerdenJ.A., FitzgibbonsR.J., WolffB.G.: Adjuvant therapy for resectable colorectal carcinoma with flourouracil administered by portal vein infusion. Arch. Surg., 125: 897–901, 1990.
13.
BeattyJ.D.: Immunotherapy of colorectal cancer. Cancer, 70: 1425–1433, 1992.
14.
BedikianA.Y., StroehleinJ.R., KarlinD.A., BennettsR.W., BodeyG.P., ValdiviesoM.: Chemotherapy for colorectal cancer with a combination of PALA and 5-FU. Cancer Treat. Rep., 65: 747–753, 1981.
15.
BenottiP., SteeleG.Jr.,: Patterns of recurrent colorectal cancer and recovery surgery. Cancer, 70: 1409–1413, 1992.
16.
BrenckmanW.D., LaufmanL.R., AdamkiewiczM.A.: Is fluorouracil (FU) plus placebo as effective as equitoxic doses of FU plus high dose oral leucovorin in colorectal cancer? Proc. ASCO, 9: 109, 1990.
17.
BrucknerH.W., MotwaniB.T.: Chemotherapy of advanced cancer of the colon and rectum. Semin. Oncol., 18: 443–461, 1991.
18.
BuyseM., Zeleniuch-JacquotteA., ChalmersT.: Adjuvant therapy of colorectal cancer: why we still don't know. JAMA, 259: 3571–3578, 1988.
19.
CampbellK.A., BurnsR.C., SitzamannJ.V.: Regional chemotherapy devices: effect of experience and anatomy on complications. J. Clin. Oncol., 3: 98–102, 1985.
20.
CampbellK.A., BurnsR.C., SitzmannJ.V.: Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J. Clin. Oncol., 3: 98–102,. 1985.
21.
ChangA.E., SchneiderP.D., SugarbakerP.H.A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann. Surg., 206: 685–693, 1987.
22.
CoiaL.R., HanksG.E.: The role of adjuvant radiation in the treatment of rectal cancer. Semin. Oncol., 18: 571–584, 1991.
23.
CollierB.D., Abdel-NabiH., DoerrR.: Immunoscintigraphy with 111In-CYT-103 in the management of colorectal carcinoma: a comparison with computed tomography. Radiology, 185: 179–186, 1992.
DanhauserL.L., FreimannJ.H., GilchristT.L., GuttermanJ.U., HunterC.Y., YeomansA.C., MarkowitzA.B.: Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alpha-2b in patients with advanced cancer. J. Clin. Oncol., 11: 751–761. 1993
26.
De GramontA., LouvetC., VarotteC., DemuynckB., BennamounM., CadyJ., GrangeJ.D., LagadecB., MaisaniJ.E., DelfauS., ChazouilleresO., LoiseauJ.P., SerokaJ., KrulikM.: Reversal of resistance to high-dose folinic acid (LV) and 5-fluorouracil (5-FU) in metastatic colorectal cancer by hydroxyurea. Proc. ASCO, 11: 178, 1992.
27.
De GramontA., LouvetC., BennamounM., VaretteC., DemuynckB., BeerblockK., MoreauS., SoubranceD., MajF., GrangeJ.D., ZylberaitD.: Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. Proc. ASCO, 11, 701, 1993.
28.
Di CostanzoF., BartolucciR., SofraM.: 5-fluorouracil alone versus high dose folinic acid and 5-FU in advanced colorectal cancer. A randomized trial of the Italian Oncology Group for Clinical Research. Proc. ASCO, 8: 109, 1989.
29.
DoroshowJ.H., MulthaufP., LeongL., MargolinK., LitchfieldT., AkamnS.: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancers in patients previously unexposed to chemotherapy. J. Clin. Oncol., 8: 491–501, 1990.
30.
DouillardJ.Y., LehurP.A., VignoudJ.: Monoclonal antibodies specific immunotherapy of gastrointestinal tumors. Hybridoma, 5: 139–149. 1986.
31.
EddyD.M.: Screening for colorectal cancer. Ann. Intern. Med., 113: 373–384, 1990.
32.
EhrlichmanC., FineS., WongA., ElhakimT.: Randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J. Clin. Oncol., 6: 469–475, 1988.
33.
EreminO., HeysS.D., CalabresiF., PeinF., RainerH., OskamR., PalmerP.A., FranksC.R.: A phase III study of recombinant interleukin-2 + 5-fluorouracil + leucovorin versus 5-FU + LV in patients with unresectable or metastatic colorectal carcinoma. Proc. ASCO, 12: 682, 1993.
34.
FabianC.J., ReddyE., JewellW., TrowbridgeA.A., McCrackenD., VogelS., GoodwingJ.W., FletcherW.S.: Phase I-II pilot of whole abdominal radiation and concomitant 5-FU as an adjuvant in colon cancer: a Southwest Oncology Group Study. J. Radiat. Oncol. Biol. Phys.;15: 885–892, 1988.
35.
FabianC., GiriS., EstesN., TangenC., PoplinB., VogelS., GoodwingW., FlemingT.: Adjuvant continuous infusion 5-FU, whole abdominal radiation and tumor bed boost in Dukes C2 colon carcinoma. A Southwest Oncology Group Pilot Study. Proc. ASCO, 12: 588, 1993.
36.
FieldingL.P., HittingerR., GraceR.H.Randomized controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet, 340: 502–506, 1992.
37.
FisherB., WolmarkN., RocketteH., RedmondC., DeutshM., WickerhamD.L., FisherE.R., CaplanR., JonesJ., LernerH., GordonP., FeldmanM., CruzA., Legault-PoissonS., WexlerM., LarenceW., RobidouxA.: Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: result from NSABP Protocol R-01. JNCI, 80: 21–29. 1988.
38.
FleischerS.B., GoldbergS.B., BrowningT.H., CooperJ.N., FriedmanE., GolodnerF., KeeffeE.B., SmithL.E.: Detection and surveillance of colorectal cancer. JAMA, 261: 580–585, 1989.
39.
Gastrointestinal Tumor Study Group:Adjuvant therapy of colon cancer: results of a prospectively randomized trial. N. Engl. J. Med., 310: 737–741, 1984.
40.
Gastrointestinal Tumor Study Group: Prolongation of the disease-free interval in surgically treated rectal carcinoma. N. Engl. J. Med., 312: 1465–1472, 1985.
41.
Gastrointestinal Tumor Study Group:Adjuvant therapy with hepatic irradiation plus fluorouracil in colon carcinoma. J. Radiat. Oncol. Biol. Phys., 21: 1151–1156. 1991.
42.
GrayB.N., deZwartJ., FisherR.: The Australia and New Zealand trial of adjuvant chemotherapy in colon cancer. In: Adjuvant Therapy for Cancer.SalmonS.E. (Ed.), pp. 537–546, Grune & Stratton, Philadelphia, 1987.
43.
GremJ.L.: Fluorinated Pyrimidines. In: Cancer Chemotherapy: Principles and Practice.ChabnerB.A., and CollinsJ.M. (Eds.), pp 18=–224, JB Lippincott, Philadelphia, 1990.
44.
GremJ., JordanE., RobsonM., BinderR., HamiltonJ.M., SteinbergS., ArbuckS., BeveridgeR., KalesA., MillerJ., WeissB., McAteeN., ChenA., GoldspielB., SaverA., AllegraC.: Phase II study of fluorouracil, leucovorin and interferon α-2A in metastatic colorectal carcinoma. J. Clin. Oncol., 11: 1737–1745, 1993.
45.
GundersonL.L., SosinH., LevittS.: Extrapelvic colon-areas of failure in a reoperation series: implications for adjuvant therapy. Int. J. Radiat. Oncol. Biol. Phys., 11: 731–741, 1985.
46.
HallerD., CannonL., AlaviA., GulfoJ.: A phase I trial of 90Y labeled monoclonal antibody B72-3 administered with concurrent EDTA in refractory adenocarcinoma. Antibody Immunocon. Radiopharm., 5: 147, 1992
HeidelbergerC., ChaudhariN.K., DannebergP.: Fluorinated pyrimidine. A new class of tumor inhibitory compounds. Nature, 179: 663–666, 1957.
49.
HohnD.C., StaggR.J., FriedmanM.A.: A randomized trial of continuous intravenous versus hepatic intraarterial fluoxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group Trial. J. Clin. Oncol., 7: 1646–1654, 1989.
50.
HooverH.C., BrandhorstJ.S., PetersL.C., SurdykeM.G., TakeshitaY., MadariagaJ., MuenzL.R., HannaM.G.: Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J. Clin. Oncol., 11: 390–399, 1993.
51.
JanikJ., KoppW.C., SmithJ.W., LongoD.L., AlvordG., SharfmanW.H., FentonR.G., SznolM., SteisR.G., Creek-moreS.P., EwelC.H., HurseyJ., UrbaW.J.: Dose-related immunologic effects of levamisole in patients with cancer. J. Clin. Oncol., 11: 125–135, 1993.
52.
JonesD.V., WinnR., PazdurR., LevinB., PughR.P., WadeJ., Liendo-LeeM., PendergrassK., AbbruzzeseJ.: A randomized phase 3 study of 5-fluorouracil and high-dose folinic acid versus 5-FU plus FA with methyl-CCNU (Me-CCNU) for patients with advanced colorectal cancer. Proc. ASCO, 12: 657; 1993.
53.
KaneM.J.: Adjuvant systemic treatment for carcinoma of the colon and rectum. Semin. Oncol., 18: 421–442, 1991.
54.
KemenyN.: Role of chemotherapy in the treatment of colorectal carcinoma. Semin. Surg. Oncol., 3: 190–214, 1987.
55.
KemenyN., DalyJ., ReichmanB.: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann. Intern. Med., 107: 459–465, 1987.
56.
KemenyN., LokichJ.J., AndersonN., AhlgrenJ.D.: Recent advances in the treatment of advanced colorectal cancer. Cancer, 71: 9–18, 1993.
57.
KemenyN., CohenA., SeiterK., ContiJ.A., SigurdsonE.R., TaoY., NiedzwieckiD., BotetJ., BuddA.: Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J. Clin. Oncol., 11: 350–355, 1993.
58.
KochaW.: 5-fluorouracil plus interferon alfa-2a versus 5-fluorouracil plus leucovorin in metastatic colorectal cancer results of a multicentre, multinational phase III study. Proc. ASCO, 12: 562, 1993.
59.
KosmidisP., TsavarisN., SkarlosD., PavlidisN., BeerM., TheocharisD., SamantaD., BriasoulisE., FountzilasG.: Fluorouracil and folinc acid with or without 2b-interferon in advanced colorectal cancer: a prospective randomized trial. Proc. ASCO, 12: 635, 1993.
60.
KrookJ.E., MoertelC.G., GundersonL.L.: Effective surgical adjuvant therapy for high risk rectal carcinoma. N. Engl. J. Med., 324: 709–715, 1991.
61.
LabiancaR., PanceraG., AitiniE., BarniS., BerettaA., BerettaG.D.: Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer; phase III study of GISCAD (Italian Group for Study of Digestive Tract Cancer). Ann. Oncol., 2: 673–679, 1991.
62.
LafferU., MetzgerU., PampallonaS., CastiglioneM.: Adjuvant intraportal chemotherapy for colorectal cancer-8-year results of the randomized Swiss Trial. Proc. ASCO, 12. 672, 1993.
63.
LaufmanL.R., BrenckmanW.D., StydnickiK.A., MorganE.D., CollierM., KnickV.B., DuchD.S., MullinR., FeroneR.: Clinical experience with leucovorin and 5-fluorouracil. Cancer, 63: 1031–1035, 1989.
64.
LaufmanL., BukowskiR., CollierM., SullivanB., McKinnisR., ClendenninN., GuaspariA., BrenckmanW.: A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol., 11: 1888–1893, 1993.
65.
LaurieJ.A., MoertelC.G., FlemingT.R., WieandH.S., LeighJ.E., RubinJ., McCormackG.W., GerstnerJ.B., KrookJ.E., MailliardJ., TwitoD.I., MortonR.F., TschetterL.K., BarlowJ.F.: Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J. Clinc. Oncol., 7: 1447–1456, 1989.
66.
LeviF., ZidaniR., VannetzelJ.M., PerpointB., FocanC., ItzhakiM., FaggiuoloR., GarufiC., CholletP., IacobeliS., O'ConnellM., PoonM., WieandH., MoertelC., KrookJ., GerstnerJ.: Biochemical modulation of 5-fluorouracil (5-FU) with leucovorin (LV). Confirmatory evidence of improved therapeutic efficacy in the treatment of advanced colorectal cancer. Proc. ASCO, 9: 106, 1990.
67.
LevinB.: Nutrition and colorectal cancer. Cancer, 70: 1723–1726, 1992.
68.
LiechmanC.G., FlemingT.R., ArdalanM.B., DuroshowJ., TangenC., MacDonaldJ.: Fluorouracil schedules and modulation in advanced colorectal cancer: a Southwest Oncology Group Screening Trial. Proc. ASCO, 12: 583, 1993.
LokichJ.J., AhlgrenJ.D., GulloJ.J., PhillipsJ.A., FreyerJ.G.: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J. Clin. Oncol., 7: 425–432, 1989.
73.
MachoverD., SchwarzenbergL., GoldschmidtE., TouraniJ.M., MichalskiB., HayatM., DorvalT., MissetJ.L., JasminC., MaralR., MatheG.: Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high dose folinic acid: a pilot study. Cancer Treat. Rep., 66: 1803–1807, 1982.
74.
MadajewiczS., Di CostanzoF., FioreJ., LiperaW., SchubachW., ViolaM., ZarrabiH., HentschelP.: Enhancement of weekly 5-FU/folinic acid (FA) with hydroxyurea modulation (FFH) for advanced cancer. A phase I study. Proc. ASCO, 10: 151, 1991.
75.
MansourE.G., LefkopoulouM., JohnsonR.: A comparison of postoperative adjuvant chemotherapy, radiotherapy or combination therapy in potentially curable resectable rectal carcinoma: an ECOG study est 4276. Proc. ASCO, 10: 154, 1991.
76.
MarangoloM., PezzuoliG., MarubiniE., AmadoriD., BoracchiP., CocconiG., CunsoloA., GarceaD., GerminianiR., LuporiniG., MalacarneP., MezzanotteG., NavaW., RebuffatC., RendaA., ZecchiniA.M., De PaloG.: Adjuvant chemotherapy with fluorouracil and CCNU in colon cancer. Results of a multicenter randomized study. Tumori, 75: 269–276, 1989.
77.
MarshJ.C., BertinoJ.R., KatzK.H., DavisC.A., DurivageH.J., RomeL.S.: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J. Clin. Oncol., 9: 371–380, 1991.
78.
MartinJ.K., O'ConnellM.J., WieandH.S.: Intraarterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch. Surg., 125: 1022–1027, 1990.
79.
MatsudaT., YasutomiM., KikuchiK., KasaiY., AbeO., KondoT., TaguchiT., HattoriT., InokuchiK., KomiN.: Cooperative study of surgical adjuvant chemotherapy for colorectal cancer (third report): five year results. Cooperative Study Group of Surgical Adjuvant Chemotherapy for Colorectal Cancer in Japan. Jap. J. Cancer Chemother., 18(3): 416–419, 1991.
80.
MayerR.J.: Chemotherapy for metastatic colorectal cancer. Cancer, 70: 1414–1424, 1992.
81.
MeadowsL.M., WaltherP., OzerH.: a-Interferon and 5-fluorouracil: possible mechanisms of antitumor action. Semin. Oncol., 18: 71–76, 1991.
82.
MellstedtH., FrödinJ.E., MasucciG., RagnhammarP., FagerbergJ., HjelmA.L., ShetyeJ., WersallP., OsterborgA.: The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin. Oncol., 18: 462–477, 1991.
83.
MetzgerU., LafferU., CastiglioneM.: Adjuvant intraportal chemotherapy for colorectal cancer-4 year results of the randomized Swiss study. Proc. ASCO, 8: 105, 1989.
84.
MitomiT., TsuchiyaS., HikiY., NotoT., OgawaN.: A randomized controlled study on adjuvant chemotherapy with UFT in curatively resected colorectal cancer. Proc. ASCO, 12: 690, 1993.
85.
MoertelC.G., FlemingT.R., MacDonaldJ.S., HallerD.G., LaurieJ.A., GoodmanP.J., UngerleiderJ.S., EmersonW.A., TormeyD.C., GlickJ.H., VeederM.H., MailliardJ.A.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med., 322: 352–358, 1990.
86.
MohiuddinM., MarksG.: Adjuvant radiation therapy for colon and rectal cancer. Semin. Oncol., 18: 411–420, 1991.
87.
MoranR.G.: Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthetase. Cancer, 63: 1008–1012, 1989.
88.
MurrayJ., StahlT.: Sphincter-saving alternatives for treatment of adenocarcinoma involving distal rectum. Surg. Clin. N. Am., 73: 131–143, 1993.
89.
National Cancer Institute Clinical Announcement: Adjuvant therapy of rectal cancer. March 14, 1991.
90.
NavoneJ., PuccioC., ChunH., WaintraubS., AhmedT., CookP., MittelmanA.: A combination of 5-fluorouracil, a-interferon, and interleukin-2 in patients with advanced colorectal adenocarcinoma. Proc. ASCO, 12: 673, 1993.
91.
NeefeJ.R., JohnW.: Mechanisms of interaction of interferon and 5-fluorouracil in solid tumors. Semin. Oncol., 18: 77–82, 1991.
92.
News: Consensus panel considers adjuvant therapy for colon and rectal cancer, identifies levamisole-fluorouracil as standard in colon cancer. Clin. Pharmacokinet, 9: 493–502, 1990.
93.
NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA, 264: 1444–1450, 1990.
94.
NobileM.T., CanobbioL., SobreroA., GalligioniE., VidiliM.G., FassioT.: A randomized trial of 5-fluorouracil and high dose leucovorin in untreated advanced colorectal cancer patients. Adv. Exp. Med. Biol., 244: 213–218, 1988.
95.
O'ConnellM.J.: A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Cancer, 63: 1026–1030, 1989.
96.
O'ConnellM., MartensonJ., RichT., WieandH., KrookJ., MacDonaldJ., HallerD., MayerR., GundersonL.: Protracted venous infusion (PVI) of 5-fluorouracil (5FU) as a component of effective combined modality postoperative survival adjuvant therapy for high-risk rectal cancer. Proc. ASCO, 12: 564, 1993.
97.
O'ConnellM., MaillardJ., MacDonaldJ., HallerD., MayerR., WieandH.: An intergroup trial of intensive course 5-FU and low dose leucovorin as surgical adjuvant therapy for high risk colon cancer. Proc. ASCO, 12: 552, 1993.
98.
PanettiereF.J., GoodmanP.J., CastanziJ.J., CruzA.B., VaitkeviciusV.K., McCrackenJ.D., BrownleeR.W., LaufmanL., StephensR.L., BonnetJ., BottomleyR., RivkinS., FletcherW., OishiN., ChenT.T.: Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group. J. Clin. Oncol., 6: 947–954, 1988.
99.
PattY.Z., McBrideC.M., AmesF.C.: Adjuvant perioperative hepatic arterial mitomycin-C and fluoxuridine combined with surgical resection of metastatic colorectal cancer in the liver. Cancer, 59: 867–873, 1987.
100.
PattY.Z., MavligitG.: Arterial chemotherapy in the management of colorectal cancer: An overview. Semin. Oncol.18: 478–490, 1991,
101.
PattY.Z.Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: the controversy continues. J. Clin. Oncol., 11: 815–819, 1993.
102.
PazdurR., AjaniJ.A., PattY.Z., WinnR., JacksonD., She-pardB., DuBrowR., CamposL., QuaraishiM., FaintuchJ., AbbruzzeseJ.L., GuttermanJ., LevinB.: Phase II study of fluorouracil and recombinant alpha-interferon 2a in previously untreated advanced colorectal carcinoma. J. Clin. Oncol.8: 2027–2031, 1990.
103.
PazdurR., BreadyB., MooreD.F.: Clinical trials of fluorouracil with α-interferon in advanced colorectal carcinomas. Semin. Oncol., 18(7S): 67–70, 1991.
104.
PazdurR., AjaniJ.A., PattY.Z., GomezJ., BreadyB., LevinB.: Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer, 71: 1214–1218, 1993.
105.
PenselR.: Advanced colon cancer: A randomized trial of fluorouracil + folinic acid and 5-FU + FA + Interferon alpha 2b. Proc. ASCO, 12: 602, 1993.
106.
PetrelliN., HerreraL., RustumY., BurkeP., CreavenP., StulcJ.: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J. Clin. Oncol., 5: 1559–1565, 1987.
107.
PetrelliN., DouglassH.O., HerreraL., RussellD.; StableinD.M., BrucknerH.W.: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J. Clin. Oncol., 7: 1419–1426, 1989.
108.
PoonM., O'ConnellM., MoertelC., WieandH., CullinanS., EversonL., KrookJ., MaillardJ., LaurieJ., TschetterL., WiesenfeldM.: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol., 7: 1407–1417, 1989.
109.
PoonM., O'ConnellM., WieandH., KrookJ., GerstnerJ., TschetterL., LevittR., KardinalC., MaillardJ.: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutich efficacy in advanced colorectal cancer. J. Clin. Oncol., 9: 1967–1972, 1991.
110.
RussellA.H., PeltonJ., ReheisC.E.: Adenocarcinoma of the colon: an autopsy study with implications for new therapeutic strategies. Cancer, 56: 1446, 1985.
111.
RustumY.M.: Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Cancer, 63: 1013–1017, 1989.
112.
RyanJ., WeidenP., CrowleyJ.: Adjuvant portal vein infusion for colorectal cancer: a 3-arm randomized trial. Proc. ASCO, 7: 95, 1988.
113.
SchilskyR.L., ChoiK.E., VokesE.E., GuaspariA., Guari-nieriC., WhalingS., LiebnerM.A.: Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing. Cancer, 63: 1018–1021, 1989.
114.
SchneebaumS., ArnoldM., MartinE.: Adjuvant treatment for rectal cancer: current status. Oncology, 7: 83–101, 1993.
115.
SearsH.F., HerlynD., SteplewskiZ.: Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastrointestinal adenocarcinoma. Hybridoma, 5: 109–115, 1986.
116.
SeifertP., BakerL.H., ReedM.D.: Comparison of continuously infused 5-fluorouracil with bolus injection in the treatment of patients with colorectal adenocarcinoma. Cancer, 36: 123–128, 1975.
117.
ShimadaY., SesakiY., SuganoK., ShiaroK., KondoH., YokotaT., SatoD., TamuraT., OheT., ShinkaiK., EguchiK., SaijoN., ShintaniS.: Phase I study of CPT-11 combined with continuous infusion of 5-fluorouracil in metastatic colorectal cancer. Proc. ASCO, 12: 575, 1993.
118.
ShimadaY., YoshinoM., WakuiA., NakooI., FutatsukiK., SakataY., KombeM., TaguchiT., OgawaN., and the CPT-11 Gastrointestinal Cancer Study Group: Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J. Clin. Oncol.11: 909–913, 1993.
119.
SigurdsonE.R., RidgeJ.A., KemenyN.: A clinical pharmacological evaluation of hepatic artery and portal vein infusion. J. Clin. Oncol., 5: 1836–1840, 1987.
120.
SinnigeH.A., ButerJ., SleijferD.T., VerschuerenR.C., MulderN.H.: Update of phase II study of 5-fluorouracil, leucovorin, and a-2A interferon in advanced colorectal cancer. Proc. ASCO, 12: 616, 1993.
121.
SkillingsJ.R., LevineM., RaynerH.L., EisenhauerE., ErlichmanC., GermondC., KerrI., LoftersW., MarounJ., YoshidaS.: Levamisole and 5-fluorouracil therapy for resected colon cancer: a new indication. Can. Med. Assoc. J., 144: 297–301, 1991.
122.
SlichenmyerW.J., RowinskyE.K., DownehowerR.C., KaufmannS.H.: The current status of camptothecin analogues as antitumor agents. JNCI, 85: 271–291, 1993.
123.
SteeleG., BledayR., MayerR.J.: A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver. Gastrointestinal Tumor Study Group, protocol 6584. J. Clin. Oncol., 9: 1105–1112, 1991.
124.
StellestagsJ., SahmondT., WagnerD.T., WilsJ., de GreveJ., BusetM., BleibergH., LacaveA., DalmarkM., NeijtJ.P.: The modulation of high-dose 5-fluorouracil with low dose methotrexate in metastatic colorectal cancer: a phase III study of the EORTC-GI Cancer Cooperative Group. Proc. ASCO, 12: 586, 1993.
125.
TakashimaS., TomitaF., SaitoH., GotodaH., KinamiY., MiyazakiI., YamaguchiA.: Clinical effect of postoperative adjuvant chemotherapy for advanced colorectal cancer-comparisons between tegafur (FT) and UFT. Jap. J. Cancer Chemother., 18: 2315–2324, 1991.
126.
TaylorI., BroomanP., RowlingJ.T.: Adjuvant liver perfusion in colorectal cancer: initial results of a clinical trial. Br. Med. J., 2: 1320–1322, 1977.
127.
TaylorI., WestC., RowingJ.: Adjuvant liver perfusion for colorectal cancer. Br. J. Surg., 68: 833–837, 1979.
128.
TaylorI., MachinD., MulleeM., TrotterG., CookeT., WestC.: A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br. J. Surg., 72: 359–363, 1985.
129.
TemperoM., BergA., BockM., HutchinsM., MoravecD., LangdonR.: A phase II trial of protracted therapy with 5-fluorouracil and leucovorin in metastatic colorectal cancer. Proc. ASCO, 12: 594, 1993.
130.
ThunM.J., CalleE.C., MohanM., NamboodiriW., FlandersD., CoatesR.J., ByersT., BoffettaP., GarfinkelL., HeathC.W.: Risk factors for fatal colon cancer in a large prospective study. JNCI, 84: 1491–1500, 1992.
131.
ValoneF.H., FriedmanM.A., WittlingerP.S., DrakesT., EisenbergP.D., MalecM.: Treatment of patients with advanced colorectal carcinoma with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J. Clin. Oncol., 7: 1427–1436, 1989.
132.
ValoneF.H., BlackP., HarperS., PhilipsK., LetvakL., Bish-koffS.: Phase II trial of 1-leucovorin given as a 138 hour continuous intravenous infusion plus 5-fluorouracil given as a daily intravenous bolus x 5 for treatment of advanced colorectal cancer. Proc. ASCO, 12: 679, 1993.
133.
Von HoffD.D.: In vitro data supporting interferon plus cytotoxic agent combinations. Semin. Oncol., 18: 58–61, 1991.
134.
WadlerS., GoldmanM., LyverA., WiernikP.: Phase I trial of 5-fluorouracil and recombinant a2a-interferon in patients with advanced colorectal carcinoma. Cancer Res., 50: 2056–2059, 1990.
135.
WagnerJ.L., HerdmanR.C., WadhwaS.: Cost-effectiveness of colorectal cancer screening in the elderly. Ann. Intern. Med., 115: 807–816, 1981.
136.
WereldsmaJ.C., BrugginkE.D., MeijerW.S.: Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil-heparin versus urokinase versus control. Cancer, 65: 425–432, 1990.
137.
WindleR., BellP.R., ShawD.: Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br. J. Surg., 74: 569–572, 1987.
138.
WolmarkN., FisherB., WieandH.S.: The prognostic value of the modifications of the Dukes’ C class of colorectal cancer. Ann. Surg., 203: 115–122, 1986.
139.
WolmarkN., FisherB., RocketteH.: Postoperative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP Protocol C-01. JNCI, 80: 30–36, 1988.
140.
WolmarkN., RocketteH., WickerhamD.L., FisherB., RedmondC., FisherE.R., PotvinM., DaviesR.J., JonesJ., RobidouxA., WexlerM., GordonP., CruzA.B., HorsleyS., NimsT.A., ThirlwellM., PhillipsW.A., PragerD., SternH.S., LernerH.J., FrazierT.G.: Adjuvant therapy of Dukes’ A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of the National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J. Clin. Oncol., 8: 1466–1475, 1990.
141.
WolmarkN., RocketteH., FisherB., WickerhamD.L., MamounasE., PerelliN.J., DimitrovN.: Leucovorin-modu-lated 5-FU as adjuvant theraphy for primary colon cancer. NSABP C-03. Proc. ASCO, 12: 578, 1993.
142.
YorkM., GrecoF.A., FiglinR.A., EinhornL., ManT., Coc-keyL., MottD., LightS.E.: A randomized phase III trial comparing 5-FU with or without interferon-a2b for advanced colorectal cancer. Proc. ASCO, 12. 590, 1993.
143.
ZaniboniA., ErichmanC., SeltzJ.F., MilanC., LabiancaR., ToriV., PignonJ.P., ZeeB., MarsoniS.: FUFA increased disease-free survival (DFS) in resected B2 and C colon cancer. Results of a prospective pooled analysis of 3 randomized trials (RCTs). Proc. ASCO, 12. 555, 1993.
